Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989541 | 0.73 | POLB (0.47) | ALDH1A1SMN1; SMN2CYP2D6MEN1KMT2A | |
| SCHEMBL6345318 | 0.72 | MEN1 (0.35) | ALDH1A1MEN1KMT2AEDNRASIRT6 | |
| SCHEMBL30380768 | 0.70 | LMNA (0.38) | ALDH1A1NPSR1SMN1; SMN2KMT2AHCAR3 | |
| SCHEMBL30380780 | 0.70 | LMNA (0.38) | ALDH1A1NPSR1SMN1; SMN2KMT2AHCAR3 | |
| SCHEMBL30381149 | 0.67 | ALDH1A1 (0.45) | MAPTALDH1A1NPSR1SMN1; SMN2MEN1 | |
| SCHEMBL30381068 | 0.67 | ALDH1A1 (0.45) | MAPTALDH1A1NPSR1SMN1; SMN2MEN1 | |
| SCHEMBL23980123 | 0.67 | SIRT6 (0.41) | ALDH1A1SMN1; SMN2SIRT6 | |
| SCHEMBL15550676 | 0.66 | ALDH1A1 (0.49) | MAPTALDH1A1SMN1; SMN2CYP2D6 | |
| SCHEMBL13061944 | 0.65 | SIRT6 (0.38) | MAPTSIRT6 | |
| SCHEMBL2270730 | 0.65 | TSHR (0.36) | MAPTALDH1A1NPSR1EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406230-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103438-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103438-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | GCKR, GCK, GALK1 | MAPT 2946/4885ALDH1A1 1454/4885NPSR1 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.